{
    "clinical_study": {
        "@rank": "129520", 
        "acronym": "DOORWAY", 
        "arm_group": {
            "arm_group_label": "Oral corticosteroids (OCS)", 
            "description": "Patient will receive 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) of Prednisone/Prednisolone (maximum 50 mg) or if vomiting OCS: 0.3 mg/kg of Dexamethasone (maximum 10 mg)"
        }, 
        "biospec_descr": {
            "textblock": "Saliva for cotinine and for DNA and nasopharyngeal samples for viral analysis."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The aim of the prospective cohort study is to: (1) document the magnitude of response to\n      oral corticosteroids administered to children presenting to the emergency department with\n      moderate or severe asthma and (2) quantify clinically available potential determinants of\n      the response to corticosteroids, such as age, gender, triggers of the index exacerbation,\n      environmental tobacco smoke (ETS), gene polymorphisms, and their interactions."
        }, 
        "brief_title": "Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "detailed_description": {
            "textblock": "The objective of the large multicentre cohort study is to quantify the response to oral\n      corticosteroids in children aged 1 to 17 years presenting to the ED with a moderate or\n      severe asthma exacerbation.\n\n      The main outcome is hospital admission within 72 hours of the oral corticosteroid\n      administration.\n\n      Secondary outcomes include the change in Pediatric Respiratory Assessment Measure (PRAM),\n      length of active treatment and other markers of response to therapy in the ED as well as\n      markers of recovery over the next 10 days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject will be eligible if he/she:\n\n               1. is aged 1 to 17 years,\n\n               2. has not received any oral, IM or IV corticosteroid within the last 5 days?\n\n               3. Presents to the hospital emergency department with an acute episode of cough,\n                  wheezing and/or dyspnea?\n\n               4. Has asthma as defined as one or more of the following 6 criteria:\n\n                  (i) prior diagnosis of asthma made by a physician; OR (ii) prior documented\n                  episode of acute cough, wheezing and/or dyspnea with significant response to\n                  inhaled \u03b22-agonists or to oral corticosteroids; OR (iii) in a child aged <2\n                  years, 3 or more episodes of cough, wheezing and/or dyspnea, including the index\n                  visit; OR (iv) previous lung function tests showing significant reversibility\n                  post-bronchodilation (\u226512% FEV1 or \u226525% Rrs at 4 to 8 Hz); OR (v) a positive\n                  provocation test (PC20 \u22648 mg/mL or Provocation Dose (to increase Rrs by 50% or\n                  more (PD50) \u22648 mg/mL), OR (vi) the current episode diagnosed or suspected of\n                  asthma by the emergency physician?\n\n               5. have moderate or severe airway obstruction, defined as a Paediatric Respiratory\n                  Asthma Measure (PRAM) score >3 at baseline,\n\n        Exclusion Criteria:\n\n          -  Patient will be excluded if :\n\n               1. he/she has another chronic respiratory condition (such as bronchopulmonary\n                  dysplasia or cystic fibrosis);\n\n               2. there is a reasonable suspicion of bronchiolitis or foreign body aspiration;\n\n               3. he/she has a prior history of hypersensitivity to salbutamol, ipratropium\n                  bromide or oral prednisone/prednisolone;\n\n               4. he/she has a relative or absolute contraindication to receiving oral\n                  corticosteroids such as recent exposure to varicella or live vaccine in past 14\n                  days,\n\n               5. there is confirmed or suspected pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "1 Year", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Children aged 1 to 17 years with moderate to severe asthma with Pediatric Respiratory\n        Assessment Measure (PRAM) \u22654."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02013076", 
            "org_study_id": "CHUSJ"
        }, 
        "intervention": {
            "arm_group_label": "Oral corticosteroids (OCS)", 
            "description": "All patients receive: (1) Prednisone or Prednisolone at 1 mg/kg (in 1 site) or 2 mg/kg (in all other sites) (max. 50 mg); if vomiting of prednisone/prednisolone: dexamethasone (0.3 mg/kg, max. 10 mg) (2) 2 to 3 doses of salbutamol within the first hour of therapy.  Those with severe exacerbations receive 3 treatments with salbutamol and ipratropium bromide within the initial hour of therapy.", 
            "intervention_name": "Oral Corticosteroids", 
            "intervention_type": "Drug", 
            "other_name": [
                "Prednisone", 
                "Prednisolone", 
                "(Dexamethasone)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Dexamethasone", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisone", 
                "Dexamethasone 21-phosphate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Asthma; Children; Cohort study; Corticosteroids", 
        "lastchanged_date": "December 11, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 2V5"
                    }, 
                    "name": "Children's Hospital of London Health Sciences Centre"
                }, 
                "status": "Completed"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L1"
                    }, 
                    "name": "Children's Hospital of Eastern Ontario"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "francine.m.ducharme@umontreal.ca", 
                    "last_name": "Francine M Ducharem, MD, M.Sc.", 
                    "phone": "1-5143454931", 
                    "phone_ext": "4398"
                }, 
                "contact_backup": {
                    "email": "bhupendrasinh.chauhan@recherche-ste-justine.qc.ca", 
                    "last_name": "Bhupendrasinh Chauhan, Ph.D.", 
                    "phone": "1-5143454931", 
                    "phone_ext": "4997"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3T1C5"
                    }, 
                    "name": "CHU Sainte-Justine (CHUSJ)"
                }, 
                "investigator": {
                    "last_name": "Francine M Ducharme, MD, M.Sc.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "dominic.chalut@muhc.mcgill.ca", 
                    "last_name": "Dominic Chalut, MD", 
                    "phone": "1-5144124400", 
                    "phone_ext": "23039"
                }, 
                "contact_backup": {
                    "email": "Dorothy.McKelvey@MUHC.MCGILL.CA", 
                    "last_name": "Dorothy McKelvey, CCRP", 
                    "phone": "1-5149341934", 
                    "phone_ext": "23833"
                }, 
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H3H 1P3"
                    }, 
                    "name": "Montreal Children's Hospital (MCH)"
                }, 
                "investigator": {
                    "last_name": "Dominic Chalut, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Quebec", 
                        "country": "Canada", 
                        "zip": "G1V 4G2"
                    }, 
                    "name": "Centre Hospitaliser de l'Universit\u00e9 Laval"
                }, 
                "status": "Terminated"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_groups": "1", 
        "official_title": "Determinants Of Oral Corticosteroid Responsiveness in Wheezing Asthmatic Youth", 
        "other_outcome": [
            {
                "description": "Number of children with vomiting, serious Infection, psychosis, and mood disturbances", 
                "measure": "Adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }, 
            {
                "description": "Number of children with adverse events requiring hospitalization, prolonged hospitalization, life threatening, other medically important events or associated with significant disability or incapacity", 
                "measure": "Serious Adverse Health Events", 
                "safety_issue": "Yes", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }
        ], 
        "overall_contact": {
            "email": "francine.m.ducharme@umontreal.ca", 
            "last_name": "Francine M Ducharme, MD, M.Sc.", 
            "phone": "1-5143454931", 
            "phone_ext": "4398"
        }, 
        "overall_contact_backup": {
            "email": "bhupendrasinh.chauhan@recherche-ste-justine.qc.ca", 
            "last_name": "Bhupendrasinh Chauhan, Ph.D.", 
            "phone": "1-51453454931", 
            "phone_ext": "4997"
        }, 
        "overall_official": {
            "affiliation": "CHU Sainte Justine, University of Montreal", 
            "last_name": "Francine M Ducharme, MD., M.Sc.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Canadian Institutes of Health Research", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Hospital admission or Length of active treatment for 8 or more hours after the oral corticosteroid administration or ED return visit associated with hospital admission within 72 hours after the oral corticosteroid administration  or ED return visit associated within 72 hours with length of active treatment for 8 or more hours after the oral corticosteroid administration", 
            "measure": "Hospital admission", 
            "safety_issue": "No", 
            "time_frame": "72 hours after oral corticosteroids administration"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02013076"
        }, 
        "responsible_party": {
            "investigator_affiliation": "St. Justine's Hospital", 
            "investigator_full_name": "Professor Francine Ducharme", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Length of active treatment in hospital", 
                "safety_issue": "No", 
                "time_frame": "8 hours after oral corticosteroid administration"
            }, 
            {
                "description": "Proportion of children with a PRAM score \u22654 within 4 hours of oral corticosteroid administration", 
                "measure": "Meeting the severity criteria for admission", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hours of oral corticosteroid administration"
            }, 
            {
                "description": "Area under the curve of the PRAM measured hourly for the time of oral corticosteroid (OCS) until 4 hours after OCS", 
                "measure": "PRAM profile in the ED", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hours of oral corticosteroid administration"
            }, 
            {
                "description": "Time until PRAM score \u2264 3", 
                "measure": "Time to meeting discharge criteria", 
                "safety_issue": "No", 
                "time_frame": "Within 8 hours of oral corticosteroid administration"
            }, 
            {
                "description": "Change in respiratory resistance between baseline and disposition will be documented on the MasterScreen Impulse Oscillometry (Cardinal Health Canada, Montreal, Canada) using previously described standardized techniques in cooperative children aged \u22653 years. (measured in a subset of individuals)", 
                "measure": "Change in respiratory resistance", 
                "safety_issue": "No", 
                "time_frame": "Within 4 hours of oral corticosteroid administration"
            }, 
            {
                "description": "unscheduled visits for asthma as reported by parents and confirmed by medical charts.", 
                "measure": "Unscheduled visits for asthma", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }, 
            {
                "description": "Area under the curve  of symptoms measured daily on the validated Asthma flare-up diary for children", 
                "measure": "Symptom score", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }, 
            {
                "description": "Duration of symptoms measured daily on the validated Asthma flare-up diary for children", 
                "measure": "Duration of asthma symptoms", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }, 
            {
                "description": "Cumulative number of puffs of reliever medication as recorded daily on the Asthma flare-up diary for children", 
                "measure": "Cumulative reliever use", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }, 
            {
                "description": "Duration of use of rescue \u00df2-agonists as recorded on the Asthma flare-up diary for children", 
                "measure": "Duration of use of rescue \u00df2-agonists", 
                "safety_issue": "No", 
                "time_frame": "Within 7 days of the index ED exacerbation"
            }
        ], 
        "source": "St. Justine's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Canadian Institutes of Health Research  (CIHR)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "St. Justine's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2013"
    }
}